ATE208813T1 - Modifizierte zellen mit resistenz gegen retroviralinfektionen - Google Patents

Modifizierte zellen mit resistenz gegen retroviralinfektionen

Info

Publication number
ATE208813T1
ATE208813T1 AT89102692T AT89102692T ATE208813T1 AT E208813 T1 ATE208813 T1 AT E208813T1 AT 89102692 T AT89102692 T AT 89102692T AT 89102692 T AT89102692 T AT 89102692T AT E208813 T1 ATE208813 T1 AT E208813T1
Authority
AT
Austria
Prior art keywords
retrovirus
disclosed
polynucleotide
resistance
nucleic acid
Prior art date
Application number
AT89102692T
Other languages
English (en)
Inventor
Wilson Greatbatch
John C Sanford
Original Assignee
Greatbatch Gen Aid Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greatbatch Gen Aid Ltd filed Critical Greatbatch Gen Aid Ltd
Application granted granted Critical
Publication of ATE208813T1 publication Critical patent/ATE208813T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT89102692T 1988-02-16 1989-02-16 Modifizierte zellen mit resistenz gegen retroviralinfektionen ATE208813T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15618888A 1988-02-16 1988-02-16

Publications (1)

Publication Number Publication Date
ATE208813T1 true ATE208813T1 (de) 2001-11-15

Family

ID=22558494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89102692T ATE208813T1 (de) 1988-02-16 1989-02-16 Modifizierte zellen mit resistenz gegen retroviralinfektionen

Country Status (4)

Country Link
US (1) US5324643A (de)
EP (1) EP0331939B1 (de)
AT (1) ATE208813T1 (de)
DE (1) DE68929343T2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658775A (en) * 1988-05-17 1997-08-19 Sloan-Kettering Institute For Cancer Research Double copy retroviral vector
US5278042A (en) * 1989-02-06 1994-01-11 The United States Of America As Represented By The Department Of Health & Human Services Method for detecting inhibitors of tat protein
WO1990011359A1 (en) * 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
AU648261B2 (en) * 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
JPH05501060A (ja) * 1990-03-21 1993-03-04 アイシス・ファーマシューティカルス・インコーポレーテッド Ｒｎａ模倣による遺伝子発現活性変調のための試薬および方法
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
DE69131848T2 (de) * 1990-05-04 2000-04-13 Isis Pharmaceuticals, Inc. Modulation der genexpression durch eingreifen in die rna sekundärstruktur
FI924964A0 (fi) * 1990-05-04 1992-11-03 Isis Pharmaceuticals Inc Modulering av genexpression genom stoerande inverkan pao sekundaerstrukturen hos rna
US5866698A (en) * 1990-05-04 1999-02-02 Isis Pharmaceuticals, Inc. Modulation of gene expression through interference with RNA secondary structure
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
EP0578776A4 (de) * 1991-04-05 1995-04-12 Edison Animal Biotech Center Hemmung von retroviren mittels zu verpackungssequenzen komplementärer antisense-nukleinsäuren.
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US6451603B1 (en) * 1992-06-29 2002-09-17 Gene Shears Pty. Limited Ribozyme nucleic acids and methods of use thereof for controlling viral pathogens
DK0664833T3 (da) * 1992-10-05 1997-04-14 Hybridon Inc Terapeutisk anti-HIV oligonukletid og lægemiddel
RU2135583C1 (ru) * 1992-11-03 1999-08-27 Байер Аг ПЛАЗМИДА ДЛЯ ЭКСПРЕССИИ АНТИ-мРНК РЕТРОВИРУСА HIV-1 (ВАРИАНТЫ)
EP0598935A1 (de) * 1992-11-24 1994-06-01 Bayer Ag Expressionsvektoren und deren Verwendung zur Darstellung HIV-resistenter menschlicher Zellen für therapeutische Anwendungen
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
AU2133695A (en) * 1994-04-06 1995-10-30 Sadna Joshi-Sukhwal Inhibition of hiv-1 multiplication in mammalian cells
US5733543A (en) * 1994-04-29 1998-03-31 Nabel; Gary J. Introduction of HIV-protective genes into cells by particle-mediated gene transfer
GB9415129D0 (en) * 1994-07-27 1994-09-14 Lynxvale Ltd Oligonucleotides and their use
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6300118B1 (en) 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5990388A (en) * 1995-06-07 1999-11-23 Research Corporation Technologies, Inc. Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein
EP0870058B1 (de) * 1995-12-14 2004-06-02 The General Hospital Corporation Verwendungen von nukleinsäuren die ein retrovirus aus schweinen entnommen sind
US6699663B1 (en) 1995-12-14 2004-03-02 The General Hospital Corporation Molecular sequence of swine retrovirus
CA2279673A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
JP2001518804A (ja) * 1997-03-21 2001-10-16 エンゾー セラピューティクス インコーポレイテッド ベクターおよびウイルスベクター、およびこれらを増殖するためのパッケージング細胞株
US8703480B1 (en) 1997-03-21 2014-04-22 Enzo Therapeutics, Inc. Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
CA2299275C (en) 1997-08-08 2009-07-07 Jaap Goudsmit Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of hiv-1
US20060183228A1 (en) * 1998-03-24 2006-08-17 Enzo Therapeutics, Inc. Viral vectors with surface or envelope components
AP1674A (en) 1999-11-16 2006-10-30 Geneart Ag The genome of the HIV-1 inter-subtype (C/B') and use thereof.
WO2001051630A1 (en) * 2000-01-07 2001-07-19 Baylor University Antisense compositions and methods
US20070037284A1 (en) * 2003-06-04 2007-02-15 Enzo Therapeutics, Inc. Vectors for expressing exogenous gene or exogenous nucleic acid sequences
CA2559955C (en) * 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
JP6340527B2 (ja) * 2013-09-20 2018-06-13 公益財団法人ヒューマンサイエンス振興財団 Ｈｔｌｖ−１プロウイルスを検出するためのキット、ｈｔｌｖ−１プロウイルスの検出方法、ｈｔｌｖ−１プロウイルスの検出装置及びプログラム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
ATE201444T1 (de) * 1985-03-21 2001-06-15 Johnston Stephen Ph D Vom parasit abgeleiteter widerstand
PT83682B (en) * 1985-11-06 1988-12-05 Smithkline Beckman Corp Process for the expression of an aids virus gene
EP0252940A4 (de) * 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Antisense-rna zur behandlung von retroviralen krankheiten.
JPS63502161A (ja) * 1986-02-14 1988-08-25 アメリカ合衆国 ヒトｔ−細胞リンパ球指向性ウイルスタイプ３の複製を抑制するプラスミド
US4935372A (en) * 1986-05-20 1990-06-19 Dana Farber Cancer Institute Art nucleotide segments, vectors, cell lines methods of preparation and use
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0291893A1 (de) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Stabile menschliche Zellinien, die ein Indikatorgenprodukt unter virusspezifischen genetischen Kontrollen exprimieren

Also Published As

Publication number Publication date
EP0331939A2 (de) 1989-09-13
EP0331939A3 (de) 1991-10-30
US5324643A (en) 1994-06-28
EP0331939B1 (de) 2001-11-14
DE68929343T2 (de) 2002-09-12
DE68929343D1 (de) 2001-12-20

Similar Documents

Publication Publication Date Title
ATE208813T1 (de) Modifizierte zellen mit resistenz gegen retroviralinfektionen
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
Volovitch et al. Studies on the single-stranded diseontinuities of the cauliflower mosaic virus genome
BG49720A3 (bg) Метод за получаване на вирусорезистентни растения
DE69434724D1 (de) Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren
TR200401186T4 (tr) Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
DK120091A (da) Tripelstrenget nukleinsyre og anvendelse heraf
ATE205253T1 (de) Induzierbare virusresistenz bei pflanzen
NO862601L (no) Ekspresjon av protein c.
CY1108240T1 (el) ΑΠΟΜΟΝΩΜΕΝΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΤΑ ΟΠΟΙΑ ΕΧΟΥΝ ΕΝΑ ΜΕΙΩΜΕΝΟ ΠΕΡΙΕΧΟΜΕΝΟ ΜΟΤΙΒΩΝ 5΄CpG3΄ ΕΠΙΓΕΝΕΤΙΚΟΥ ΕΛΕΓΧΟΥ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΟΥΣ
ATE48140T1 (de) Modifizierte nukleotide und verfahren zu ihrer herstellung und anwendung.
BR9811096A (pt) Sequências, moléculas, vetores e vacinas de dna recombinante para doença do calcivìrus felino e processo para a produção e o uso dos mesmos
Osaki et al. Nucleotide sequences of double-stranded RNA segments from a hypovirulent strain of the white root rot fungus Rosellinia necatrix: possibility of the first member of the Reoviridae from fungus
Raskó et al. Genes in Medicine: Molecular biology and human genetic disorders
Wayne Davies et al. Nucleotide sequence of the attachment site of coliphage lambda
WO1995005460A3 (en) Feline immunodeficiency virus isolate ncsu 1
GR3015892T3 (en) Virus resistant plants having a viral coat protein.
Kolata Z-DNA Moves Toward" Real Biology" Once considered to be an oddity of no particular significance, this unusual structure is now showing up in DNA segments that control gene expression
DE59209908D1 (de) Verfahren zur genetischen Manipulation von Myxobakterien
DE69331216D1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
DE69132828D1 (de) Resistenzgene gegen Fusarsäure
DE69025907D1 (de) Nukleinsäurefragmente und vom HHV6/SIE Virusgenom abgeleitete Diagnosemittel sowie Verfahren zur Diagnose von HHV6 Infektionen
Takahashi et al. Induction of mutation invitro in phage φX174 am3 by N4-aminodeoxycytidine triphosphate
Maurizot et al. Interaction between the peptide lysyl-tryptophanyl-lysine and copolynucleotides of adenine and uracil: Selectivity of interaction
RU93018105A (ru) Штамм рекомбинантного вируса осповакцины, вызывающий иммунитет против вируса венесуэльского энцефаломиелита лошадей в организме животных, и способ его получения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties